Matches in Wikidata for { <http://www.wikidata.org/entity/Q45963526> ?p ?o ?g. }
- Q45963526 description "2014 nî lūn-bûn" @default.
- Q45963526 description "2014年の論文" @default.
- Q45963526 description "2014年学术文章" @default.
- Q45963526 description "2014年学术文章" @default.
- Q45963526 description "2014年学术文章" @default.
- Q45963526 description "2014年学术文章" @default.
- Q45963526 description "2014年学术文章" @default.
- Q45963526 description "2014年學術文章" @default.
- Q45963526 description "2014年學術文章" @default.
- Q45963526 description "2014年學術文章" @default.
- Q45963526 description "2014年學術文章" @default.
- Q45963526 description "2014年學術文章" @default.
- Q45963526 description "2014年學術文章" @default.
- Q45963526 description "2014년 논문" @default.
- Q45963526 description "article científic" @default.
- Q45963526 description "article scientific" @default.
- Q45963526 description "article scientifique (publié 2014)" @default.
- Q45963526 description "articol științific" @default.
- Q45963526 description "articolo scientifico" @default.
- Q45963526 description "artigo científico (publicado na 2014)" @default.
- Q45963526 description "artigo científico (publicado na 2014)" @default.
- Q45963526 description "artigo científico" @default.
- Q45963526 description "artikull shkencor" @default.
- Q45963526 description "artikulong pang-agham" @default.
- Q45963526 description "artykuł naukowy" @default.
- Q45963526 description "artículo científico publicado en 2014" @default.
- Q45963526 description "artículu científicu" @default.
- Q45963526 description "bilimsel makale" @default.
- Q45963526 description "bài báo khoa học" @default.
- Q45963526 description "mokslinis straipsnis" @default.
- Q45963526 description "naučni članak" @default.
- Q45963526 description "scienca artikolo" @default.
- Q45963526 description "scientific article" @default.
- Q45963526 description "teaduslik artikkel" @default.
- Q45963526 description "tieteellinen artikkeli" @default.
- Q45963526 description "tudományos cikk" @default.
- Q45963526 description "vedecký článok" @default.
- Q45963526 description "vetenskaplig artikel" @default.
- Q45963526 description "videnskabelig artikel (udgivet 2014)" @default.
- Q45963526 description "vitenskapelig artikkel" @default.
- Q45963526 description "vitskapeleg artikkel" @default.
- Q45963526 description "vědecký článek" @default.
- Q45963526 description "wetenschappelijk artikel" @default.
- Q45963526 description "wissenschaftlicher Artikel" @default.
- Q45963526 description "επιστημονικό άρθρο" @default.
- Q45963526 description "мақолаи илмӣ" @default.
- Q45963526 description "мақолаи илмӣ" @default.
- Q45963526 description "наукова стаття, опублікована в липні 2014" @default.
- Q45963526 description "научна статия" @default.
- Q45963526 description "научная статья" @default.
- Q45963526 description "научни чланак" @default.
- Q45963526 description "научни чланак" @default.
- Q45963526 description "գիտական հոդված" @default.
- Q45963526 description "מאמר מדעי" @default.
- Q45963526 description "سائنسی مضمون" @default.
- Q45963526 description "مقالة علمية" @default.
- Q45963526 description "مقالهٔ علمی" @default.
- Q45963526 description "২০১৪-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
- Q45963526 description "บทความทางวิทยาศาสตร์" @default.
- Q45963526 description "სამეცნიერო სტატია" @default.
- Q45963526 name "Reply to the letter to the editor 'clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC' by Ou et al." @default.
- Q45963526 name "Reply to the letter to the editor 'clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC' by Ou et al." @default.
- Q45963526 type Item @default.
- Q45963526 label "Reply to the letter to the editor 'clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC' by Ou et al." @default.
- Q45963526 label "Reply to the letter to the editor 'clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC' by Ou et al." @default.
- Q45963526 prefLabel "Reply to the letter to the editor 'clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC' by Ou et al." @default.
- Q45963526 prefLabel "Reply to the letter to the editor 'clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC' by Ou et al." @default.
- Q45963526 P1433 Q45963526-F0F23A46-6452-41F7-9F95-9238D60C704E @default.
- Q45963526 P1476 Q45963526-23A62A11-61D9-46DC-B827-4AD22B3958FA @default.
- Q45963526 P2093 Q45963526-6381A580-643C-4550-A77E-83B04E9A6AE0 @default.
- Q45963526 P2093 Q45963526-819EB9A3-F975-4E12-B308-4E2CE9194DCB @default.
- Q45963526 P2860 Q45963526-0E17860C-A439-43BB-B05C-8AF183DD3677 @default.
- Q45963526 P2860 Q45963526-2D3976C7-E956-487E-AC25-C8ABEE388303 @default.
- Q45963526 P2860 Q45963526-84C2A425-C45B-4A93-90B0-ACB9360C343A @default.
- Q45963526 P2860 Q45963526-B9185100-5E2E-4FED-B608-1AA6DE507062 @default.
- Q45963526 P2860 Q45963526-D3980ED4-2D08-4BC8-B3DA-CE932CE2BCED @default.
- Q45963526 P2860 Q45963526-F4443B15-E09F-4684-B289-EF2A5C58140B @default.
- Q45963526 P304 Q45963526-932E8A63-D612-41C8-A94F-40A6D548B5D6 @default.
- Q45963526 P31 Q45963526-C27355AD-2538-4CB4-9D76-F741E2D9D286 @default.
- Q45963526 P356 Q45963526-1D1BC615-E964-48B8-8E5F-E855100CEF71 @default.
- Q45963526 P433 Q45963526-AE9A0EC5-D57A-44FB-8169-EDD4B3E2DC4B @default.
- Q45963526 P478 Q45963526-DBE56E2E-6500-4174-A335-485D12A11B5B @default.
- Q45963526 P577 Q45963526-61FAA90A-B520-45E2-A014-143754BDD7A3 @default.
- Q45963526 P5875 Q45963526-FBBFDD94-061F-48DA-A7A6-E6AE0258A996 @default.
- Q45963526 P698 Q45963526-8F2E2961-32A3-4E92-8807-C0315E88057E @default.
- Q45963526 P921 Q45963526-B0227FD4-7C1E-4D6F-A34D-377956D30C9C @default.
- Q45963526 P356 MDU258 @default.
- Q45963526 P698 25035278 @default.
- Q45963526 P1433 Q326122 @default.
- Q45963526 P1476 "Reply to the letter to the editor 'clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC' by Ou et al." @default.
- Q45963526 P2093 "J Pasi" @default.
- Q45963526 P2093 "S-H I Ou" @default.
- Q45963526 P2860 Q27682565 @default.
- Q45963526 P2860 Q27852806 @default.
- Q45963526 P2860 Q37003248 @default.
- Q45963526 P2860 Q41871009 @default.
- Q45963526 P2860 Q45972765 @default.
- Q45963526 P2860 Q48439820 @default.
- Q45963526 P304 "2093" @default.
- Q45963526 P31 Q13442814 @default.